At the news
? MIXEDIMPACT 7/10 425 filed Jun 15, 2026 at 07:49 ET
Nano Dimension announced a non-binding term sheet to merge with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, in a stock-for-stock deal valuing Infinite at $890 million. Existing Nano shareholders would retain a meaningful minority stake in the combined company (to be renamed Infinite Epigenetics, ticker IEAI) based on a 20% premium to Nano's estimated net cash at closing, with the combined entity expected to have over $400 million in cash. The deal is transformative but non-binding, subject to definitive agreement, due diligence, shareholder votes, and regulatory approvals, with a key shareholder vote on July 31, 2026, to authorize continuation of the strategic process.
- Nano Dimension entered a non-binding term sheet to acquire Infinite Epigenetics in a stock-for-stock merger valuing Infinite at $890 million.
- Existing Nano shareholders expected to retain meaningful minority ownership based on a 20% premium to Nano's estimated net cash at closing.
- Combined company to operate as Infinite Epigenetics on Nasdaq under ticker IEAI, with over $400 million in cash at closing.
- Infinite Epigenetics has collected 120,000+ epigenetic samples since 2020 and targets a $90B+ U.S. clinical diagnostics market.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access